

Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression

Nando Reza Pratama^{1,a}, Ifan Ali Wafa^{1,a}, David Setyo Budi^{1,a}, Henry Sutanto², Tri Pudy Asmarawati³, Citrawati Dyah Kencono Wungu^{4,5,*}

¹Faculty of Medicine, Universitas Airlangga, Indonesia

²Department of Physiology and Pharmacology, State University of New York (SUNY) Downstate Health Sciences University, New York, USA

³Department of Internal Medicine, Universitas Airlangga Hospital, Universitas Airlangga, Indonesia

⁴Institute of Tropical Disease, Universitas Airlangga, Indonesia

⁵Department of Physiology and Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Indonesia

Word Count: main text = 3687

Correspondence:

Citrawati Dyah Kencono Wungu, MD., PhD.

Department of Physiology and Medical Biochemistry, Airlangga University

Jalan Mayjen Prof. Dr. Moestopo No.47, Surabaya, Indonesia

Email: citrawati.dyah@fk.unair.ac.id

^aThese authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Summary

Background: There is a need for evaluation regarding vaccine effectiveness (VE) and the urgency of booster vaccination against Covid-19 B.1.1.529 (Omicron) variant.

Methods: Systematic search was conducted on April 6th, 2022, on databases (PubMed, ScienceDirect, CENTRAL, Web of Science, Scopus). VE difference (VED) estimates were assessed using random-effects model and DerSimonian-Laird tau estimators. Two models result, i.e., within 3 months and within 3 months or more, are compared. VE versus time meta-regression analysis was evaluated using mixed-effects model with Restricted-Maximum Likelihood tau estimators and Hartung-Knapp adjustments.

Findings: Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 vaccines were included in the analyses. Compared to full dose, booster dose of overall vaccines provided better protection against any (VED=22% (95% CI 15%-29%), $p<0.001$), severe (VED=20% (95% CI 8%-32%), $p=0.001$) and symptomatic (VED=22% (95% CI 11%-34%), $p<0.001$) Omicron infections within 3 months, as well as within 3 months or more (VED=30% (95% CI 24%-37%), $p<0.001$ for any, VED=18% (95% CI 13%-23%), $p<0.001$ for severe and VED=37% (95% CI 29%-46%), $p<0.001$ for symptomatic infections). The meta-regression analysis of overall vaccines revealed that the full dose VE against any and symptomatic Omicron infections were significantly reduced each month by 3.0% (95% CI 0.9%-4.8%, $p=0.004$) and 5.2% (95% CI 3.3%-7.1%, $p=0.006$), respectively; whereas booster dose effectiveness against severe and symptomatic Omicron infections were decreased by 3.7% (95% CI 5.1%-12.6%, $p=0.030$) and 3.9% (95% CI 1.2%-6.5%, $p=0.006$), respectively.

Interpretation: Compared to full dose only, a booster dose addition provides better protection against B.1.1.529 infection. Although the VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 vaccines against B.1.1.529 infection after both full and booster doses are generally moderate, and the booster dose provides excellent protection against severe infection, it is important to note that the VE estimates decline over time, suggesting the need for a regular Covid-19 booster injection after certain period of time to maintain VE.

Keywords: COVID-19; SARS-CoV-2; Omicron variant; vaccine effectiveness; booster vaccination.

1 INTRODUCTION

2 As of April 2022, there were at least two circulating SARS-CoV-2 variants of concern:
3 the B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants.¹ In November 2021, the Omicron
4 variant was first identified in South Africa and was immediately declared a variant of concern
5 by the World Health Organization. Alongside the massive rise in the confirmed cases of SARS-
6 CoV-2 infection in South Africa, the Omicron variant started to spread across the globe in no
7 time. The identification of several concerning mutations in the SARS-CoV-2 Omicron variant
8 and evidences of an enhanced immune escape ability contributed to the rapid spread of the
9 Omicron variant worldwide.² Compared to the ancestral variants (Wuhan-Hu-1 or Wuhan-1),
10 the Omicron variant contains more mutations (i.e., 60 mutations), 32 of which occur in the
11 spike gene which encodes the primary antigen target for a wide variety of Covid-19 vaccines.³
12 These mutations have been linked to increased transmissibility, a high rate of immune evasion
13 following natural infection and vaccination, and the impairment of the efficacy of SARS-CoV-
14 2 vaccines.⁴

15 Vaccine effectiveness (VE) is a measure of how well vaccines protect people from
16 infections in the real world setting.⁵ It played a critical role in restricting the spreading of
17 SARS-CoV-2 infections in the current Covid-19 pandemic.⁶ Earlier in the Covid-19 pandemic,
18 studies predicted a 60-90% herd immunity threshold to limit the disease spreading, which could
19 be achieved through several measures, including a mass vaccination campaign.^{7,8} Indeed,
20 several Covid-19 vaccines have been shown to be promising by numerous large randomized-
21 controlled trials (RCTs).⁹⁻¹³ Since then, many countries have extensively implemented Covid-
22 19 vaccination programs. However, prior laboratory and clinical studies have indicated a
23 reduction in VE against the Omicron variant as compared to the earlier variants¹⁴⁻¹⁶, potentially
24 affecting the current Covid-19 vaccination strategy. Therefore, with the surge of new SARS-
25 CoV-2 variants, booster vaccine doses were administered to confer stronger immunity, which
26 hopefully could increase VE.^{17,18} However, due to global disparity in the availability,
27 distribution of COVID-19 vaccines and the vaccination rates, developing countries were
28 pushed to expedite booster vaccination with (limited) available resources to foster their booster
29 vaccination rates.^{19,20}

30 Since an equal distribution of booster vaccines remains a challenge and Omicron's
31 spike antigen landscape is heavily altered, there is a need for explorations regarding the
32 effectivity of currently available vaccines and the urgency of booster vaccination against
33 SARS-CoV-2 Omicron variant. Here, we performed systematic review and meta-analysis to

34 unravel the effectiveness of full and booster vaccinations against the SARS-CoV-2 Omicron
35 variant.

36 **METHODS**

37 This systematic review conformed with the guidelines of Preferred Reporting Items for
38 Systematic Review and Meta-Analysis (PRISMA) 2020²¹ and has been registered in the
39 PROSPERO database ([CRD42022302267](#)).

40 **Eligibility Criteria**

41 This review included any study designs, including RCT, cohort, case-control, and cross-
42 sectional studies. Studies were selected according to the following criteria: (1) administration
43 of Covid-19 vaccine during the Omicron variant's wave as the study of interest; (2) eligible
44 studies reporting at least one of our outcomes of interest; and (3) English language. Our
45 outcomes included VE difference (VED) between the booster and full dose, the correlation of
46 booster dose VE with time, and the correlation of full dose VE with time. We excluded review
47 articles, nonhuman studies, irrelevant articles, and duplications.

48 **Search Strategy and Selection of Studies**

49 Two authors (I.A.W and D.S.B) conducted a keyword search for articles published in databases
50 (PubMed, ScienceDirect, Cochrane Central Register of Controlled Trials [CENTRAL], Web
51 of Science, and Scopus) up to April 6th, 2022. Extended manual search (e.g., in medRxiv,
52 bioRxiv) and bibliographical search were also conducted to obtain additional potential articles.
53 The following keywords were used: “((SARS-CoV-2) OR (COVID-19)) AND ((Omicron) OR
54 (B.1.1.529)) AND ((Vaccine) OR (Vaccination)) AND ((Vaccine efficacy) OR (Vaccine
55 effectiveness))” Detailed search strategies are available in *Supplementary Materials*. We
56 exported all studies retrieved from the electronic search into the Mendeley reference manager
57 for duplication removal and independent screening. Any disagreements between these two
58 authors were resolved by discussion with all authors until consensus was reached. The number
59 of excluded studies were specified in the PRISMA flow diagram alongside their reasons for
60 exclusion (**Figure 1**).

61 **Data Extraction**

62 Two review authors (N.R.P and D.S.B) independently extracted relevant data from each
63 selected study using a structured and standardized form. For each included study, the following
64 relevant data were collected: first authors' names and publication year, study design, country
65 of origin, sample size, patient age, Omicron strain confirmation method, follow-up duration,
66 dose, types and administration interval of Covid-19 vaccines, endpoints, and VE.

67 **Quality Assessment**

68 The methodological quality of each study was assessed independently by two authors (I.A.W
69 and D.S.B) using the original Newcastle-Ottawa Scale (NOS) for case-control and cohort
70 studies.²² The tool evaluates the quality of observational studies from the following 3 domains:
71 (1) sample selection; (2) study comparability; and (3) study outcome. The NOS contains 8
72 items with scores ranging from 0 to 9. The total score of 0–3, 4–6, and 7–9 indicated low-,
73 moderate-, and good-quality studies, respectively. Any discrepancies were resolved by
74 discussion until consensus was reached.


75 **Statistical Analysis**

76 Primary analyses were carried out using R version 4.0.5 with meta and dmetar package. VE
77 was defined as $(1-OR) \times 100\%$, $(1-RR) \times 100\%$ or $(1-HR) \times 100\%$. VED was defined as the
78 difference of VE between the booster and full dose vaccines, i.e., VE of booster dose – VE of
79 full dose. We used the I^2 test to quantify the heterogeneity between studies, with values $I^2 > 50\%$
80 representing moderate-to-high heterogeneity. Random effects were used with the inverse
81 variance method for pooling the results and DerSimonian-Laird for estimating τ^2 . Egger's test
82 was performed for the evaluation whether publication bias analyses were indicated. All
83 statistical analyses with a p-value < 0.05 was considered statistically significant. Leave-one-out
84 sensitivity analysis was conducted to find the source of statistical heterogeneity and
85 demonstrate how each study influenced the overall result. Meta-regression analysis was also
86 performed using inverse-variance and Restricted-Maximum Likelihood with Hartung-Knapp
87 adjustment. VE reduction per month was approximated by multiplying the VE reduction per
88 day—the slope of VE versus (vs) time—by 30.

89 **RESULTS**

90 **Study Selection and Quality Assessment**

91 From databases and manual search, 1,278 and 786 records were retrieved, respectively. A total
92 of 147 duplicates were subsequently removed. Following the screening of titles and abstracts,
93 60 potential articles were selected for review. After a full-text review, 21 observational studies,
94 consisting of 5 cohorts and 16 test-negative case-control studies, were included in the
95 systematic review, meta-analysis, and meta-regression. The overall screening process of this
96 systematic review and meta-analysis is summarized in the PRISMA flow diagram (**Figure 1**).
97 The quality assessment of each study using the NOS critical appraisal checklist is listed in
98 **Table S2 and S3**. All included studies were considered good-quality studies according to the
99 quality assessment.



100

101 **Figure 1.** Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram of study selection process²¹

102 **Table 1.** Characteristics of the included studies

Reference	Study Design	County of Origin	Sample Sizes	Age /years	Omicron strain Confirmation Method	Follow up duration & (median (IQR)) or Range) ⁺ /days		Type of Vaccines	Endpoints	Vaccine effectiveness [§] /100%
						Dose 2	Dose 3			
Buchan et al., 2021 ²³	Case-control [^]	Canada	134,435	≥ 18	Viral whole genome or S-gene sequencing	NR	NR	BNT162b2, mRNA-1273	Symptomatic infection and severe infection	1-OR
Gray et al., 2021 ²⁴	Case-control [^]	South Africa	52,468	≥ 18	Omicron period	N/A	0-13 days group 8 (5-11) days 14-27 days group 20 (17-24) days 1-2 months group 32 (29-34) days	Ad26.COV2	Positive Covid-19 and severe infection	1-OR
Accorsi et al., 2022 ²⁵	Case-control [^]	United States	70,155	≥ 18	Viral ORFlab, S, and N gene sequencing	8.0 (1.0) months	1.0 (1.0) month	BNT162b2, mRNA-1273	Symptomatic infection	1-OR

Andrews et al., 2022 ²⁶	Case-control [^]	United Kingdom	2,663,549	≥ 18	Viral whole genome and S-gene sequencing	NR	39 (range, 14-118)	ChAdOx1, BNT162b2, mRNA-1273	Symptomatic infection	1-OR
Chemaitelly et al., 2022 ²⁷	Case-control [^]	Qatar	133,327	No restriction	Viral whole genome sequencing	NR	NR	BNT162b2, mRNA-1273	Symptomatic infection	1-OR
Collie et al., 2022 ²⁸	Case-control [^]	South Africa	211,610	≥ 18	Viral S-gene sequencing	NR	NR	BNT162b2	Symptomatic infection and severe infection	1-OR
Ferdinand et al., 2022 ²⁹	Case-control [^]	United States	93,408	≥ 18	Omicron-predominance period	214 (164-259)	49 (30-73)	Mixture of mRNA vaccines***	Symptomatic infection*	1-OR
Klein et al., 2022 ³⁰	Case-control [^]	United States	39,217	≥ 18	Omicron-predominance period	5 to 11 y.: 14-67 12-15 y.: NR 16-17 y.: NR	NR	BNT162b2	Symptomatic infection*	1-OR

Lauring et al., 2022 ³¹	Case-control [^]	United States	11,690	≥ 18	Viral whole genome sequencing	NR	69.5 (41.5-97)	Mixture ^{**}	Severe infection	1-OR
Natarajan et al., 2022 ³²	Case-control [^]	United States	80,287	≥ 18	Omicron-predominance period	Ad26.COV 2.S: 52 (33-71) Mixture: 48 (32-71)	Median (IQR) 59 (38-79)	Mixture of mRNA vaccines ^{***}	Symptomatic infection* and Hospitalization	1-OR
Tartof et al., 2022 ³³	Case-control [^]	United States	14,137	≥ 18	Viral whole genome and S-gene sequencing	NR	NR	BNT162b2	Symptomatic infection and severe infection	1-OR
Tenforde et al., 2022 ³⁴	Case-control [^]	United States	7544	≥ 18	Omicron-predominance period	256	60	Mixture of mRNA	Severe infection [#]	1-OR
Thompson et al., 2022 ³⁵	Case-control [^]	United States	222,772	≥ 18	Omicron-predominant period	< 180 days group: 137 ≥ 180 days group: 223	Median interval: 41-44	Mixture of mRNA vaccines ^{***}	Positive Covid-19 and severe infection	1-OR
Tseng et al., 2022 ³⁶	Case-control [^]	United States	136,345	≥ 18	Viral whole genome and S-gene sequencing	14-365 days	NR	mRNA-1273	Positive Covid-19 and severe infection	1-OR

Young-Xu et al., 2022 ³⁷	Case-control [^]	United States	6,9215	≥ 18	Omicron-predominant period	NR	NR	Mixture ^{**}	Positive Covid-19	1-OR
Zambrano et al., 2022 ³⁸	Case-control [^]	United States	283	12-18 years	Viral genome sequencing	MIS-C: 63 (48-89)	N/A	BNT162b2	Severe infection ^{&}	1-OR
Abu-Raddad et al., 2022 ³⁹	Retrospective Cohort	Qatar	2,239,193	No restriction	Viral genome sequencing	21 (11-38)	22 (12-38)	BNT162b2, mRNA-1273	Symptomatic infection and severe infection	1-HR
Hansen et al., 2021 ⁴⁰	Retrospective Cohort	Denmark	5,767	≥ 12 and ≥ 60	Sequencing of viral whole genome or a novel variant specific targeting the 452L mutation	1-150	1-30	BNT162b2, mRNA-1273	Positive Covid-19	1-HR
Monge et al., 2022 ⁴¹	Retrospective Cohort	Spain	6,222,318	≥ 40	Omicron-predominant period	0-34	0-34	ChAdOx1-S, Ad26.COV2.S, mRNA-1273, BNT162b2	Positive Covid-19	1-RR

Šmíd et al., 2022 ⁴²	Retrospective Cohort	Czech Republic	8,282,080	No restriction	Viral genome sequencing	NR	NR	BNT162b2, mRNA-1273	Symptomatic infection and Hospitalization	1-HR
Fowlkes et al., 2022 ⁴³	Prospective cohort	United States	1,364	5 to 18	Viral genome sequencing	5 to 11 y.: 14-82 12 to 15 y.: NR	N/A	BNT162b2	Any infection	1-HR

103 Data obtained from the emergency department and urgent care.

104 †Data from IMV or hospital-related death.

105 ‡Multisystem Inflammatory Syndrome in children (MIS-C).

106 †The number shows a median (IQR) or range between dose receipt date and endpoint date. The purpose is to depict how data distribution between booster and full dose differ.

107 If the study did not report the limit of follow up interval, then it would be written as not reported. A detailed outcome summary with 95%CI is compiled in **Table S4** and

108 **Table S5** for full and booster doses, respectively.

109 †Test-negative case-control study design.

110 ‡1-OR is 1-(odds among vaccinated group)/(odds among unvaccinated group); 1-RR is 1-(risk among vaccinated group)/(risk among unvaccinated group); 1-HR is

111 1-(hazard among vaccinated group)/(hazard among unvaccinated group)).

112 †Mixture is designated for studies that do not specify the type of vaccines. It does not necessarily mean that the vaccines are heterologous or mix-and-matched.

113 ††Mixture of mRNA vaccines is designated for studies that describe the vaccines as mRNA vaccines but do not specify further the name of vaccines.

114 Abbreviation: MIS-C, Multisystem Inflammatory Syndrome in children; N/A, not available; NR, not reported; y., year.

115 Study Characteristics


116 We included 21 studies, consisting of 5 cohorts and 16 test-negative case-control studies with
117 a total of 20,691,164 participants. Four types of Covid-19 vaccine (i.e., Ad26.COV2.S,
118 BNT162b2, ChAdOx1 nCov-19, and mRNA-1273) were included in the VE analyses of the
119 full and booster doses. Full dose vaccination represents 2 doses of BNT162b2, ChAdOx1
120 nCov-19 and mRNA-1273 vaccines, or 1 dose of Ad26.COV2.S vaccines, whereas booster
121 dose vaccination was defined as the administration of an extra dose of Covid-19 vaccine on top
122 of the full dose vaccination. Two studies^{31,37} did not specify the type of vaccines being used;
123 therefore, in this study, we defined it as a mixture. However, it does not necessarily mean that
124 the vaccines are heterologous or mix-and-matched. Four studies^{29,32,34,35} used mRNA vaccines
125 but did not further specify the manufacturers. In this case, we defined them as a mixture of
126 mRNA vaccines. Two studies^{38,43} evaluated the effectiveness of Covid-19 vaccines only among
127 children and adolescents, while the rest of the studies included adults as their participants.
128 Geographically, the included studies were originated from 8 countries/locations: 12 studies
129 were conducted in the United States, 4 studies in Europe, 2 studies in South Africa, 2 studies
130 in Qatar, and 1 study in Canada. The follow-up time intervals varied among studies. Between
131 booster and full doses, only 3 studies^{32,39,41} had a similar median or range from the date of dose
132 receipt to the date of endpoint events.^{32,39,41} The VE was calculated as $(1-OR) \times 100\%$ among
133 all case-control studies, while VE among cohort studies was calculated as $(1-OR) \times 100\%$,
134 $(1-RR) \times 100\%$, or $(1-HR) \times 100\%$ (**Table 1**). The VE from each study with its 95% clinical
135 interval (CI) for full and booster doses are summarized in **Table S4** and
136 **Table S5**, respectively. The results of VED calculation are summarized in **Table S6**.

137 Outcomes Measure


138 We evaluated three outcomes, i.e., VED between the booster and full dose, correlation of
139 booster dose VE with time, and correlation of full dose VE with time. We further evaluated
140 each of these outcomes for three different endpoints: any, symptomatic and severe Omicron
141 infections. The ‘any infection’ outcome included positively-tested Covid-19, symptomatic
142 Covid-19, and severe Covid-19. Meanwhile, the ‘symptomatic infection’ endpoint comprised
143 any individuals who had been tested positive and showed Covid-19 symptoms. Individuals who
144 require hospital visits without hospitalization were also included. Those who were hospitalized
145 due to Covid-19, regardless of the received treatment, were deemed as having a severe
146 infection. For VED between the full and booster doses, we analyzed the results using 2 models:

147 the ‘within 3 months’ and the ‘within 3 months or more’ models. The ‘within 3 months’ model
 148 included data in the first 3 months reported by each study and the ‘within 3 months or more’
 149 model included data in the first 3 months or more reported by each study.

150 **VED Estimates Between Booster and Full Dose**



151



152

153 **Figure 2.** Forest Plot summary representing VED between the booster and a full dose of Covid-19 vaccine
 154 against SARS-CoV-2 infections. Panel A and B show subgroup summary of VED 'within 3 months' and 'within
 155 3 months or more' models, respectively.

156 *Overall analysis*

157 Results from two meta-analysis models, i.e. 'within 3 months' (**Figure 2A**) and 'within 3
 158 months or more' (**Figure 2B**) models, were compared. In the 'within 3 months' model, there
 159 were 22 separate analysis data involving BNT162b2 (k = 8), ChAdOx1 nCov-19 (k = 1),
 160 Mixture (k = 2), Mixture of mRNA vaccines (k = 7), and mRNA-1273 (k = 4),. Meanwhile, in
 161 the 'within 3 months or more' model, we obtained 28 separate analysis data that involved
 162 BNT162b2 (k = 9), ChAdOx1 nCov-19 (k = 1), Mixture (k = 2), Mixture of mRNA vaccines
 163 (k = 10), and mRNA-1273 (k = 6). As a comparison between these two models, pooled results
 164 of the 'within 3 months or more' model generally had a higher VED, but for severe infection,
 165 the pooled results yielded somewhat similar VED.

166 In the 'within 3 months' model, the pooled results for preventing any, severe and
 167 symptomatic infections showed that booster dose had a significantly higher VE than that of the

168 full dose (VED of 22% (95%CI 15% to 29%), 20% (95%CI 8% to 32%), and 22% (95%CI
169 11% to 34%), respectively). In the ‘within 3 months or more’ model, the pooled results also
170 showed a better VE on booster dose for any, severe and symptomatic infections (VED of 30%
171 (95%CI 24% to 37%), 18% (95%CI 13% to 23%), and 37% (95%CI 29% to 46%),
172 respectively).

173 The heterogeneity of overall and subgroup analyses is summarized in **Table S15** and
174 **Table S16**. Leave-one-out sensitivity analyses performed on the overall analysis yielded
175 similar results in terms of effect estimates or statistical heterogeneity if each study was omitted
176 from the pooled results calculation (**Figure S1-S6**).

177 *Subgroup analysis of ‘within 3 months’ model*

178 For any infection, the cohort subgroup had a VED of 35% (95%CI 14% to 57%), but results
179 obtained from the case-control subgroup showed a lower VED, with a VED of 17% (95%CI
180 13% to 21%). A further subgroup analysis with respect to vaccine type showed that BNT162b2,
181 ChAdOx1 nCov-19, Mixture, Mixture of mRNA vaccines, and mRNA-1273 had VEDs of 25%
182 (95%CI 8% to 41%), 16% (95%CI 2% to 30%), 27% (95%CI -1% to 55%), 15% (95%CI 6%
183 to 24%) and 25% (95%CI 4% to 47%), respectively. These results were statistically significant
184 except that of the Mixture subgroup.

185 For severe infection, cohort and case-control subgroups showed significant results
186 (VEDs of 34% (95%CI 16% to 52%) and 13% (95%CI 5% to 20%), respectively). A further
187 subgroup analysis showed that the VED of BNT162b2, Mixture, and Mixture of mRNA
188 vaccines were 22% (95%CI 9% to 35%), 42% (95%CI 32% to 52%), and 12% (95%CI 3% to
189 21%), respectively. All of these results were also statistically significant.

190 For symptomatic infection, cohort and case-control subgroups also showed VEDs of
191 51% (95%CI 49% to 53%) and 17% (95%CI 12% to 22%), respectively. In the BNT162b2,
192 ChAdOx1 nCov-19, and Mixture of mRNA vaccines subgroups, the booster dose had a better
193 VE than that of the full dose (VED of 25% (95%CI 5% to 46%), 16% (95%CI 2% to 30%), and
194 17% (95%CI 1% to 33%), respectively). These results were statistically significant, except for
195 the mRNA-1273 vaccine subgroup, the result did not reach statistical significance (VED of
196 23% (95%CI -7% to 54%)).


197 *Subgroup analysis of ‘within 3 months or more’ model*

198 For any infection, the cohort subgroup had a VED of 43% (95%CI 22% to 64%), but results
199 obtained from the case-control subgroup showed a lower VED, with a VED of 27% (95%CI
200 21% to 34%). A further subgroup analysis with respect to vaccine type showed that,
201 BNT162b2, ChAdOx1 nCov-19, mixture of mRNA vaccines, and mRNA-1273 had VEDs of
202 40% (95%CI 28% to 52%), 27% (95%CI 14% to 41%), 21% (95%CI 14% to 27%), and 36%
203 (95%CI 22% to 50%), respectively. All these results were statistically significant, except that
204 of Mixture subgroup with the VED of 29% (95%CI -4% to 62%).

205 For severe infection, cohort and case-control subgroups showed significant results
206 (VEDs of 35% (95%CI 13% to 57%) and 11% (95%CI 5% to 17%), respectively). A further
207 subgroup analysis showed that the VED of BNT162b2 vaccine was 22% (95%CI 9% to 35%),
208 while the VEDs of Mixture and Mixture of mRNA vaccines were 46% (95%CI 34% to 58%),
209 11% (95%CI 3% to 18%), respectively. All these results were statistically significant, except
210 that of mRNA-1273 subgroup with the VED of 15% (95%CI -24% to 54%).

211 For symptomatic infection, cohort and case-control subgroups also showed significant
212 results with VEDs of 51% (95%CI 49% to 53%) and 34% (95%CI 25% to 44%), respectively.
213 In the BNT162b2, ChAdOx1 nCov-19, mixture of mRNA vaccines, and mRNA-1273
214 subgroups, the booster dose also presented a better VE than that of the full dose (VEDs of 40%
215 (95%CI 26% to 55%), 27% (95%CI 14% to 41%), 28% (95%CI 20% to 36%), and 41%
216 (95%CI 25% to 56%), respectively). All of these results were statistically significant.

217 **VE Estimates and VE reduction for Booster Dose and Full Dose**



218

219 **Figure 3.** Meta-regression plot for VE vs Time in days. VE on panel A, B, and C represent VE of full dose against
220 any infection, severe infection, and symptomatic infection, respectively. VE on panel D, E, and F represent VE of
221 booster dose against any infection, severe infection, and symptomatic infection, respectively. VE estimate (%)
222 was 50.12 (95%CI 37.78 to 62.46), $p < 0.001$ (A); 68.28 (95%CI 48.71 to 87.85), $p < 0.001$ (B); 58.21 (95%CI 46.26
223 to 70.15), $p < 0.001$ (C); 66.04 (95%CI 55.32 to 76.75), $p < 0.001$ (D); 93.96 (95%CI 88.3 to 99.63), $p < 0.001$ (E);
224 65.03 (95%CI 54.59 to 75.48), $p < 0.001$ (F).

225 In the meta-regression analysis, the VE of full vaccination dose against any (**Figure**
226 **3A**) and symptomatic (**Figure 3C**) infections were significantly correlated with time ($p =$
227 0.0036, and $p < 0.001$, respectively), whereas the VE of full vaccination dose against severe
228 infection was not (0.705). The VE of booster vaccination dose against symptomatic (**Figure**
229 **3E**) and severe (**Figure 3F**) infections were significantly correlated with time ($p = 0.030$ and
230 $p = 0.006$, respectively), while the VE of booster vaccination dose against any infection was
231 not ($p = 0.1051$). The correlation of VE (%) with time (day) was 50.12 - 0.1 per day (**Figure.**
232 **3A**); 68.28 - 0.018 per day (**Figure. 3B**); 58.21 - 0.173 per day (**Figure. 3C**); 66.04 - 0.077 per
233 day (**Figure. 3D**); 93.96 - 0.054 per day (**Figure. 3E**); 65.03 - 0.129 per day (**Figure. 3F**).

234 For the full dose vaccination, our meta-regression model estimated that the VE of full
235 dose against any and symptomatic infections were decreased in each month approximately by
236 3.0% (95%CI 0.9% to 4.8%) and 5.2% (95%CI 3.3% to 7.1%), respectively. Meanwhile, the
237 VE of booster dose against severe and symptomatic infections were decreased in each month
238 by 3.7% (95%CI 5.1% to 12.6%) and 3.9% (95%CI 1.2% to 6.5%), respectively. The detailed
239 results displaying the correlation of VE with time for each vaccine were presented in **Table 2**.

240 **Table 2.** VE estimates and VE reduction for booster dose and full dose of each vaccine.

Vaccine	Full vaccination dose			Booster vaccination dose		
	k	VE estimate (%) (95% CI)	VE reduction (% per month) (95% CI)	k	VE estimate (%) (95% CI)	VE reduction (% per month) (95% CI)
Any infection						
Overall Results	93	50.12 (37.78 to 62.46), p<0.001	-2.955 (-4.92 to -0.99), p:0.004	52	66.04 (55.32 to 76.75), p<0.001	-2.31 (-5.12 to 0.50), p:0.105
Ad26.COVS2.S	2	59.94* (-22.34 to 142.22), p:0.069	N/A	5	69.16 (-13.52 to 151.85), p:0.076	-22.36 (-78.98 to 34.26), p:0.298
BNT162b2	38	54.62 (35.57 to 73.66), p<0.001	-4.82 (-7.85 to -1.79), p:0.003	20	69.79 (54.94 to 84.65), p<0.001	-5.44 (-8.99 to -1.89), p:0.005
ChAdOx1 nCov-19***	6	56.03 (47.81 to 64.25), p<0.001	-8.532 (-9.98 to -7.09), p<0.001	2	51.45* (-4.97 to 107.86), p:0.055	N/A
Mixture	4	69.35 (-1.91 to 140.62), p:0.053	-12.78 (-34.95 to 9.39), p:0.131	7	58.29 (-15.68 to 132.26), p:0.099	2.76 (-20.07 to 25.59), p:0.768
Mixture of mRNA vaccines****	25	62.47 (36.03 to 88.91), p<0.001	-1.54 (-5.14 to 2.07), p:0.387	10	88.23 (72.01 to 104.46), p<0.001	-1.68 (-4.97 to 1.61), p:0.273
mRNA-1273****	18	51.80 (29.39 to 74.21), p<0.001	-5.34 (-8.973 to -1.707), p:0.007	8	66.54 (49.43 to 83.65), p<0.001	-3.72 (-12.58 to 5.15), p:0.344
Severe infection						
Overall Results	15	68.28 (48.71 to 87.85), p<0.001	-0.54 (-3.52 to 2.45),	Overall Results	15	68.28 (48.71 to 87.85), p<0.001
Ad26.COVS2.S	1	67* (52 to 77), p<0.05	N/A	2	86.0* (10.82 to 161.19), p:0.044	N/A

BNT162b2 ^{**}	4	89.88 (50.39 to 129.38), p:0.010	-2.715 (-9.177 to 3.747), p:0.213	2	89.05* (86.39 to 91.71), p:0.002	N/A
ChAdOx1 nCov-19	0	N/A	N/A	0	N/A	N/A
Mixture	2	35.93 [#] (-64.80 to 136.66), p: 0.138	N/A	3	89.34 (-157.54 to 336.22), p:0.136	-1.17 (-69.903 to 67.566), p:0.865
Mixture of mRNA vaccines ^{****}	8	83.9 (62.22 to 105.58), p<0.001	-2.23 (-5.06 to 0.60), p:0.102	5	95.26 (89.19 to 101.34), p<0.001	-1.43 (-2.90 to 0.027), p:0.052
mRNA-1273	0	N/A	N/A	1	99.2 ^{*+} (76.3 to 100), p<0.05	N/A
Symptomatic infection						
Overall Results	59	58.21 (46.26 to 70.15), p<0.001	-5.202 (-7.116 to -3.285), p<0.001	32	65.03 (54.59 to 75.48), p<0.001	-3.858 (-6.492 to -1.221), p:0.006
Ad26.COVS.S	1	54* (43 to 63), p<0.05	N/A	0	N/A	N/A
BNT162b2	27	58.38 (46.09 to 70.67), p<0.001	-5.91 (-7.761 to -4.056), p<0.001	17	68.79 (59.21 to 78.38), p<0.001	-6.423 (-8.898 to -3.948), p<0.001
ChAdOx1 nCov-19	6	56.03 (47.81 to 64.25), p<0.001	-8.532 (-9.978 to -7.089), p<0.001	2	51.45* (-4.97 to 107.86), p:0.055	N/A
Mixture	0	N/A	N/A	3	59.99 (-1121.52 to 1241.51), p:0.635	-1.998 (-343.083 to 339.09), p:0.953
Mixture of mRNA vaccines ^{****}	15	55.62 (14.08 to 97.15), p:0.013	-1.893 (-8.079 to 4.293), p:0.520	5	76.66 (34.59 to 118.73), p:0.010	-1.119 (-8.862 to 6.621), p:0.677
mRNA-1273 ^{***}	10	76.11 (62.22 to 90), p<0.001	-9.558 (-12.09 to -7.029), p<0.001	5	78.44 (30.98 to 125.9), p:0.013	-16.152 (-53.139 to 20.835), p:0.259

241
242

Statistically significant if p<0.05.

^{**}The full dose VE estimate for the corresponding vaccine reaches statistical significance but does not significantly correlate with day.

243 †††The booster dose VE estimate for the corresponding vaccine reaches statistical significance but does not significantly correlate with day.
244 ††††Both full and booster dose VE estimates for the corresponding vaccine reach statistical significance, but do not significantly correlate with day.
245 †The VE estimate is calculated from meta-analysis and meta-regression is not performed.
246 †The VE estimate is the same as what has been reported in the original study; neither meta-analyses nor meta-regression is performed.
247 †This data is not part of meta-regression analysis because the time latitude cannot be estimated.
248 †VE reduction per month is approximated by multiplying the VE reduction per day—the slope of VE vs time—by 30.
249 Abbreviation: k, number of analyses; N/A, not available; VE, vaccine effectiveness.

250 DISCUSSION

251 This study aimed to evaluate the full dose and booster VE, and their correlation with time to
252 evaluate waning immunity. We used two models for VED evaluation based on time period,
253 i.e., ‘within 3 months’ and ‘within 3 months or more’. Our models demonstrated that there was
254 a significant VED between the booster and full dose in terms of preventing any, symptomatic
255 and severe infections of the SARS-CoV-2 Omicron variant. Although these results had a
256 generally high heterogeneity, subgroup analyses showed that study design and types of vaccine
257 did not seem to contribute to this heterogeneity. However, VED at a more prolonged interval
258 model, i.e. ‘within 3 months or more’, was more elevated. Most analyses at a longer interval
259 contained more full dose vaccine data since the follow-up interval for the full vaccination dose
260 was considerably longer than that of the booster dose.

261 On the other hand, our meta-regression analysis showed that the full dose VE against
262 any and severe infections were estimated to be reduced by 3.0% and 5.2% each month,
263 respectively. Meanwhile, the booster dose VE against severe and symptomatic infections were
264 estimated to be reduced by 3.7% and 3.9% each month, respectively. Additionally, VE
265 estimates of booster dose were generally higher than that of full dose, in line with VED meta-
266 analysis results. VE estimates of booster doses were generally at more than 60% for all
267 endpoints. Booster doses of mRNA vaccines showed excellent protection against severe
268 infection with a VE of 95.26%, compared to full dose with a VE of 83.9%. This result was in
269 agreement with the prediction by Khoury *et al.*⁴⁴ In that study, it was predicted that a booster
270 dose could raise VE from 81.1%, by full dose, to 98.2% for mRNA vaccines. Also, in that
271 study, BNT162b2 and mRNA-1273 were predicted to have more than 80% VE against severe
272 infection, and VE against severe infection was generally higher than that of symptomatic
273 infection.⁴⁴

274 Vaccination or natural infection induces some immune cell subsets to turn into memory
275 cells through clonal expansions.⁴⁵ These previously primed cells could deliver a more robust
276 immune response in the secondary response, which is protective against severe disease.
277 Meanwhile, neutralizing antibodies can provide sterilizing immunity to prevent infection.⁴⁵⁻⁴⁷
278 Neutralizing antibodies produced by plasma B cells decay over time, but long-lived plasma B
279 memory cells continuously secrete neutralizing antibodies even after the infection ends,
280 maintaining their level.⁴⁸ Moreover, a robust immune response and multiple infections or
281 vaccination can elicit strong immunoglobulin G (IgG)-binding affinity as a result of an affinity

282 maturation process.^{49,50} Consequently, compared to full vaccination doses, an additional
283 booster vaccination dose would elicit a stronger immune response,⁵¹ as evidenced by some
284 studies that reported a higher binding affinity and titers of neutralizing antibodies among
285 individuals who received three vaccination doses than that of two doses.⁵¹⁻⁵³ For instance, with
286 regard to the Omicron variant, the antibody titer induced by a booster dose of BNT162b2 at 1
287 month were 23-fold higher than that of full dose recipients.⁵⁴

288 Some studies showed that neutralizing antibody titers in Covid-19 were predictive of
289 immune protection.^{55,56} Neutralization titers continuously declined and appeared to be short-
290 lived,^{57,58} and immune escape was observed in several SARS-CoV-2 variants of concern,⁵⁹⁻⁶²
291 leading to reduced VE to some extent.⁵⁷ The immune escape may cause a reduced VE among
292 variants of concern, regardless of how long the last vaccination is given before the infection. A
293 meta-analysis with modeling study has previously demonstrated the correlation between
294 neutralization titers with VE.⁵⁷

295 The magnitude of VE reduction depends on the initial efficacy. The VE against
296 symptomatic infection could drop, by day 250, to 77% or 33% if initial efficacy was 95% or
297 70%, respectively.⁶³ Thus, the efficacy of a vaccine may vary across types of vaccine, doses,
298 and variants. The study by Khoury *et al.*⁴⁴ estimated that neutralizing antibody levels needed
299 to protect from severe infection were 6-fold lower than symptomatic infection, which could
300 explain the reason why the VE against severe infection in our study remained high, despite the
301 low VE against symptomatic infection.⁶³ Since short-lived or substantial decay of neutralizing
302 antibody titers means an increased vulnerability towards symptomatic infection, a persistent
303 cellular immune memory enables a faster and stronger secondary immune response.^{64,65} An
304 appropriate secondary immune response, especially T-cell response, is protective against
305 severe infection.⁶⁶⁻⁶⁸

306 Our analyses showed a moderate VE reduction against the Omicron variant.
307 Nonetheless, the Omicron variant did not display an increased severity despite the increased
308 transmissibility.⁶⁹⁻⁷¹ Our results showed that VE estimates against severe infection still exhibit
309 a high efficacy for both the full and booster doses. However, we should be aware that new
310 variants of concern may emerge anytime, and always need to be anticipated. Maintaining the
311 Covid-19 pandemic to a low endemic level is seemingly a reasonable target before the
312 eradication of Covid-19 could be achieved.

313 We acknowledge that this study has some limitations. First, most results had high
314 heterogeneity. In the meta-analysis of VED outcome, we attempted to perform subgroup
315 analyses based on the study design and types of the vaccine, but the heterogeneity remained

316 high. Since there was a considerable discrepancy in the follow-up time between the booster
317 and full doses, we suspected that the high heterogeneity was due to covariate time, as we have
318 demonstrated in the other outcomes. Secondly, all included studies were observational studies.
319 In observational studies, some confounding factors are difficult to measure, thereby cannot be
320 controlled. For example, significant differences in the follow-up time would result in different
321 exposure received between the two groups. Moreover, the fact that VE declines over time
322 should be considered because cumulative comparison would lead to a bias. As the result, we
323 attempted to limit the time interval in one model to only include data within three months to
324 minimize this bias. Third, some included studies were obtained from preprint servers, which
325 had not been preceded by a peer-review process and the presented data may differ from the
326 final published, peer-reviewed, version.

327 **CONCLUSION**

328 A lower initial VE supports the evidence that the SARS-CoV-2 Omicron variant has an
329 increased immune escape ability, and the decline of VE over time indicates the presence of
330 waned immunity in the SARS-CoV-2 Omicron variant infection. The VE of the booster dose
331 was generally higher than that of the full dose. Although VE remained high in both the full and
332 booster doses for severe infections, a booster vaccination dose is still recommended to confer
333 utmost protection against the SARS-CoV-2 Omicron variant infection. Moreover, the
334 emergence of other variants of concern should always be anticipated. Nevertheless, these meta-
335 analyses and meta-regression were constructed upon observational studies, in which several
336 confounders adjustment could be difficult to perform. Therefore, future RCTs might be able to
337 address several limitations of this study.

338 **Contributors**

339 NRP, IAW, DSB developed the study design, data collection, data analysis, and writing
340 (Original Draft Preparation). HS contributed to the writing (Review and Editing), manuscript
341 validation, and supervision. TPA developed the study design, methodology, manuscript
342 validation, and supervision. CDKW developed the study design, data analysis, methodology,
343 manuscript validation, supervision. All authors reviewed and approved the final manuscript.

344 **Declaration of interests**

345 The authors have declared no competing interest.

346 **Funding**

347 This study did not receive any funding.

348 **Data Sharing**

349 The protocol for the systematic review is available at:
350 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022302267. Detailed
351 methods, results, and additional data are available in the manuscript and the associated
352 appendix.

REFERENCES

1. Tracking SARS-CoV-2 variants. <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>.
2. Science Brief: Omicron (B.1.1.529) Variant | CDC. <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html>.
3. Pajon, R. *et al.* SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. *New England Journal of Medicine* **386**, 1088–1091 (2022).
4. Araf, Y. *et al.* Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. *Journal of Medical Virology* vol. 94 1825–1832 (2022).
5. Principles of Epidemiology | Lesson 3 - Section 6. <https://www.cdc.gov/csels/dsepd/ss1978/lesson3/section6.html>.
6. Luring, A. S. & Hodcroft, E. B. Genetic Variants of SARS-CoV-2 - What Do They Mean? *JAMA - Journal of the American Medical Association* vol. 325 529–531 (2021).
7. Anderson, R. M., Vegvari, C., Truscott, J. & Collyer, B. S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. *The Lancet* vol. 396 1614–1616 (2020).
8. Randolph, H. E. & Barreiro, L. B. Herd Immunity: Understanding COVID-19. doi:10.1016/j.immuni.2020.04.012.
9. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine* **383**, 2603–2615 (2020).
10. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine* **384**, 403–416 (2021).
11. Sadoff, J. *et al.* Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New England Journal of Medicine* **384**, 2187–2201 (2021).
12. Xia, S. *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *The Lancet Infectious Diseases* **21**, 39–51 (2021).
13. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99–111 (2021).
14. Garcia-Beltran, W. F. *et al.* mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* **185**, 457-466.e4 (2022).
15. Fang, Z. *et al.* Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. *bioRxiv* 2022.02.14.480449 (2022) doi:10.1101/2022.02.14.480449.
16. Li, M., Lou, F. & Fan, H. SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines. *Signal Transduction and Targeted Therapy* vol. 7 (2022).
17. Bar-On, Y. M. *et al.* Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *New England Journal of Medicine* **385**, 1393–1400 (2021).

18. Zeng, G. *et al.* Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *The Lancet Infectious Diseases* **22**, 483–495 (2022).
19. Zinatizadeh, M. R. *et al.* Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. *Biomedicine and Pharmacotherapy* vol. 146 (2022).
20. CDC COVID Data Tracker: Global COVID-19 Vaccinations. <https://covid.cdc.gov/covid-data-tracker/#global-vaccinations>.
21. Page, M. J. *et al.* The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *The BMJ* vol. 372 (2021).
22. Wells, G. *et al.* The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. *undefined* (2014).
23. Buchan, S. A. *et al.* Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. *medRxiv* 2021.12.30.21268565 (2022) doi:10.1101/2021.12.30.21268565.
24. Gray MBBCH, G. E. *et al.* Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COVID during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study. *medRxiv* 2021.12.28.21268436 (2021) doi:10.1101/2021.12.28.21268436.
25. Accorsi, E. K. *et al.* Association between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. *JAMA - Journal of the American Medical Association* **327**, 639–651 (2022).
26. Andrews, N. *et al.* Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. *medRxiv* 2021.12.14.21267615 (2021) doi:10.1101/2021.12.14.21267615.
27. Chemaitelly, H. *et al.* Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar. *medRxiv* 2022.02.07.22270568 (2022) doi:10.1101/2022.02.07.22270568.
28. Collie, S., Champion, J., Moultrie, H., Bekker, L.-G. & Gray, G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. *New England Journal of Medicine* **386**, 494–496 (2022).
29. Ferdinands, J. M. *et al.* Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, Aug. *MMWR Recommendations and Reports* **71**, 255–263 (2022).
30. Klein, N. P. *et al.* Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network. *MMWR Recommendations and Reports* **71**, 352–358 (2022).
31. Lauring, A. S. *et al.* Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective

- Observational Study. *medRxiv* 2022.02.06.22270558 (2022)
doi:10.1101/2022.02.06.22270558.
32. Natarajan, K. *et al.* Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COVS.2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION . *MMWR. Morbidity and Mortality Weekly Report* **71**, 495–502 (2022).
 33. Tartof, S. Y. *et al.* BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design. *SSRN Electronic Journal* (2022)
doi:10.2139/ssrn.4011905.
 34. Tenforde, M. W. *et al.* Effectiveness of mRNA Vaccination in Preventing COVID-19 – Associated Invasive Mechanical Ventilation and Death — United States , March 2021 – January 2022. **71**, 459–465 (2022).
 35. Thompson, M. G. *et al.* Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022. *MMWR. Morbidity and Mortality Weekly Report* **71**, 139–145 (2022).
 36. Fu Tseng, H. *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. *medRxiv* 2022.01.07.22268919 (2022)
doi:10.1101/2022.01.07.22268919.
 37. Young-Xu, Y. *et al.* Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans. *medRxiv* 2022.01.15.22269360 (2022)
doi:10.1101/2022.01.15.22269360.
 38. Zambrano, L. D., Newhams, M. M., Olson, S. M., Halasa, N. B. & Price, A. M. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12 – 18 Years — United States , July – December 2021. **71**, 52–58 (2022).
 39. Abu-Raddad, L. J. *et al.* Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar. *medRxiv* 2022.01.18.22269452 (2022) doi:10.1101/2022.01.18.22269452.
 40. Holm, C. *et al.* TITLE PAGE Title: Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. *medRxiv* 2021.12.20.21267966 (2021) doi:10.1101/2021.12.20.21267966.
 41. Monge, S. *et al.* The Effectiveness of mRNA Vaccine Boosters for Laboratory-Confirmed COVID-19 During a Period of Predominance of the Omicron Variant of SARS-CoV-2. *SSRN Electronic Journal* (2022) doi:10.2139/ssrn.4035396.
 42. Šmíd, M. *et al.* Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2. *medRxiv* (2022).
 43. Fowlkes, A. L. *et al.* Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and

- Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022. *MMWR. Morbidity and Mortality Weekly Report* **71**, 422–428 (2022).
44. Khoury, D. S. *et al.* A meta-analysis of Early Results to predict Vaccine efficacy against Omicron. *medRxiv* 2021.12.13.21267748 (2021) doi:10.1101/2021.12.13.21267748.
 45. Ratajczak, W., Niedźwiedzka-Rystwej, P., Tokarz-Deptuła, B. & Deptuła, W. Immunological memory cells. *Central European Journal of Immunology* vol. 43 194–203 (2018).
 46. Stevenson, F. K., Genova, G. di, Ottensmeier, C. & Savelyeva, N. Cancer Vaccines. in *Cancer Immunotherapy* 183–204 (Elsevier Inc., 2007). doi:10.1016/B978-012372551-6/50075-4.
 47. Kyei-Barffour, I., Addo, S. A., Aninagyei, E., Ghartey-Kwansah, G. & Acheampong, D. O. Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. *Biomedicine and Pharmacotherapy* vol. 144 753–3322 (2021).
 48. Palm, A. K. E. & Henry, C. Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination. *Frontiers in immunology* vol. 10 1787 (2019).
 49. Smith, K. G. C., Light, A., Nossal, G. J. V. & Tarlinton, D. M. The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response. *EMBO Journal* **16**, 2996–3006 (1997).
 50. Khurana, S. *et al.* Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans. *Nature Communications* **10**, 1–15 (2019).
 51. Munro, A. P. S. *et al.* Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. *The Lancet* **398**, 2258–2276 (2021).
 52. Choi, A. *et al.* Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nature Medicine* **27**, 2025–2031 (2021).
 53. Gray, K. J. *et al.* Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. *American Journal of Obstetrics and Gynecology* **225**, 303.e1–303.e17 (2021).
 54. Muik, A. *et al.* Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. *Science (1979)* **375**, 678–680 (2022).
 55. Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* **39**, 4423–4428 (2021).
 56. Koch, T. *et al.* Correlates of Vaccine-Induced Protection against SARS-CoV-2 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD). (2021) doi:10.3390/vaccines9030238.
 57. Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe* **3**, e52–e61 (2022).
 58. Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *New England Journal of Medicine* **385**, e84 (2021).

59. Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nature Reviews Microbiology* vol. 19 409–424 (2021).
60. Starr, T. N., Greaney, A. J., Dingens, A. S. & Bloom, J. D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. *Cell Reports Medicine* **2**, 100255 (2021).
61. Mlcochova, P. *et al.* SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* **599**, 41 (2021).
62. Sun, C. *et al.* Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. *Signal Transduction and Targeted Therapy* **7**, 1–10 (2022).
63. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Medicine* **27**, 1205–1211 (2021).
64. Altmann, D. M. & Boyton, R. J. SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. *Science Immunology* vol. 5 (2020).
65. Rodda, L. B. *et al.* Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell* **184**, 169-183.e17 (2021).
66. Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501.e15 (2020).
67. Pollard, A. J. & Bijker, E. M. Publisher Correction: A guide to vaccinology: from basic principles to new developments (Nature Reviews Immunology, (2021), 21, 2, (83-100), 10.1038/s41577-020-00479-7). *Nature Reviews Immunology* vol. 21 129 (2021).
68. Weiskopf, D. *et al.* Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Science Immunology* **5**, (2020).
69. Ren, S.-Y., Wang, W.-B., Gao, R.-D. & Zhou, A.-M. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. *World J Clin Cases* **10**, 1–11 (2022).
70. Iuliano, A. D. *et al.* Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022. *MMWR. Morbidity and Mortality Weekly Report* **71**, 146–152 (2022).
71. Baker, J. M. *et al.* SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022. *MMWR. Morbidity and Mortality Weekly Report* **71**, 341–346 (2022).